PHARVARIS NV

PHARVARIS insiders trade under a 10 b5‑1 plan, buying low at $2.59 and selling high around $40, reflecting a disciplined strategy that boosts investor confidence while hinting at future dilution risks.

Glassman’s latest 8,000‑share buy of Pharvaris NV at $32 signals insider confidence in the B2 antagonist pipeline, hinting at future upside and strategic liquidity.

Modig Berndt’s steady insider sales at PHARVARIS NV reveal a disciplined vesting strategy—not a sign of doubt, but liquidity moves that keep confidence high while the company eyes clinical gains.

Insider selling at Pharvaris NV: President Lu Peng sells 226 shares at €34‑35, hinting at short‑term pressure amid a promising oral B2 antagonist pipeline.

Insider sale by Pharvaris CEO Modig Berndt adds 2,292 shares at €34.97, a planned move in a high‑valuation window that keeps investor confidence steady while funding future trials.

Insight on Pharvaris NV insider sales: Schikan’s 10(b)(5) trades may signal short‑term profit‑taking while fundamentals remain bullish for long‑term investors.

Insider sales at Pharvaris: CEO Modig Berndt’s routine 2,191‑share June sale reflects rule‑based liquidity, not a strategic shift, but a rising trend may hint at take‑profit sentiment.

Pharvaris insider sales reveal routine portfolio moves, not loss of faith, yet investors should watch clinical milestones and price volatility.

Insider moves reveal Pharvaris NV’s strategic shift, with key buys at €8.05 and sales at €29.32—an insider‑confidence signal for investors.

Pharvaris NV insider selling rises—CEO Modig Berndt sells thousands of shares at $29.22, sparking short‑term volatility amid a strong 101% annual gain and promising oral B2 antagonist pipeline. Invest with insight.